Agios Presents Data on AG-221 - Analyst Blog

Agios Pharmaceuticals, Inc. ( AGIO ) announced new encouraging data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies.

The data was presented at the European Hematology Association (EHA) in Italy. The new data confirmed the previously presented data on AG-221's clinical activity, safety profile and unique mechanism of action.

It was observed in the study that AG-221 showed favorable drug exposure and pharmacokinetics at all doses tested with substantial reductions in plasma levels of the oncometabolite 2-hydroxyglutarate (2HG). Moreover, it was observed that AG-221 was well tolerated.

We note that AG-221 is one of the most advanced candidates in Agios' pipeline. The candidate is being evaluated for the treatment of patients suffering from acute myelogenous leukemia (AML).

Based on promising safety and efficacy data from the studies so far on AG-221, Agios plans to initiate four expansion cohorts in the second half of 2014 - relapsed/refractory AML patients aged 60 years and above, relapsed/refractory AML patients aged under 60 years, untreated AML patients who decline standard of care chemotherapy, and patients with other IDH2 mutant positive hematologic malignancies (such as lymphoma, multiple myeloma, etc.).

Agios, a biopharmaceutical company, focuses on the treatment of patients suffering from cancer and inborn errors of metabolism (IEM).

The lead candidates in the cancer pipeline are AG-221 and AG-120, targeting mutant isocitrate dehydrogenase 2 and 1 while the lead candidate in the IEM program is AG-348.

Agios is developing AG-221 under a collaboration agreement with Celgene Corporation ( CELG ).

Celgene recently exercised its exclusive option to license AG-221, thereby gaining worldwide development and commercialization rights for AG-221 while Agios continues to conduct early clinical development and regulatory activities within the AG-221 development program.

Agios Pharma currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the healthcare sector may consider companies like Gilead Sciences ( GILD ) and Allergan ( AGN ). Both stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AGIOS PHARMACT (AGIO): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More